Shin Nippon Biomedical Laboratories (SNBL)
8
23M
6
0.12
0.25
2
- Areas of investment
Summary
Shin Nippon Biomedical Laboratories (SNBL) is the famous Corporate Investor, which was founded in 1957. The company was established in Asia in Japan. The main office of represented Corporate Investor is situated in the Tokyo.
The top activity for fund was in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. The increased amount of exits for fund were in 2019. Opposing the other organizations, this Shin Nippon Biomedical Laboratories (SNBL) works on 21 percentage points more the average amount of lead investments.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Shin Nippon Biomedical Laboratories (SNBL), startups are often financed by National Science Foundation, TPG Biotech, RA Capital Management. The meaningful sponsors for the fund in investment in the same round are tella, Nikon, Dainippon Sumitomo Pharma. In the next rounds fund is usually obtained by Mitsubishi UFJ Capital, incTANK Ventures, Tohoku University Venture Partners.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular fund investment industries, there are Therapeutics, Medical. Among the various public portfolio startups of the fund, we may underline Agrivida, TMS Co., Ltd., Healios K.K The fund has specific favorite in a number of founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.12
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (7)
- Pharmaceutical (3)
- Health Care (3)
- Medical (3)
- Life Science (2) Show 10 more
- Investments by region
-
- United States (3)
- Japan (5)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Satsuma Pharmaceuticals | 24 Apr 2019 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 62M | United States, California, South San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.